Fronto-temporal tDCS Mproves Fluency & Empathy in ASD Kids

NCT ID: NCT02004236

Last Updated: 2024-09-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Interventional, prospective, randomized, double-blind, placebo-controlled and parallel assignment study, in which patients with Autism Spectrum Disorder (ASD) are two types of intervention by transcranial random noise stimulation (tRNS), to improve verbal fluency and empathy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interventional, prospective, randomized, double-blind, placebo-controlled and parallel assignment study, in which patients receive three types of intervention tRNS: one group received 35 sessions focused on the fronto-temporal cortex, another group received 35 sessions focused on the temporal fusiform cortex and last placebo group was operated with 35 sessions tRNS. After brain noninvasive stimulation sessions, a blind analysis of the improvement in verbal fluency and empathy in patients with autism spectrum disorder is made. For each patient included a follow up period of three months will be established.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism ASD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tRNS Fronto-temporal cortex

This group receive 35 sessions of tRNS over fronto-temporal cortex

Group Type EXPERIMENTAL

tRNS Fronto-temporal cortex

Intervention Type DEVICE

This group receive 35 sessions of tRNS over fronto-temporal cortex

tRNS over fusiform temporal cortex

This group receive 35 sessions of tRNS over fusiform temporal cortex

Group Type EXPERIMENTAL

tRNS over fusiform temporal cortex

Intervention Type DEVICE

This group receive 35 sessions of tRNS over fusiform temporal cortex

tRNS with sham

This group receive 35 sessions with sham

Group Type PLACEBO_COMPARATOR

tRNS with sham

Intervention Type DEVICE

the subjects receive 35 session with sham

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tRNS Fronto-temporal cortex

This group receive 35 sessions of tRNS over fronto-temporal cortex

Intervention Type DEVICE

tRNS over fusiform temporal cortex

This group receive 35 sessions of tRNS over fusiform temporal cortex

Intervention Type DEVICE

tRNS with sham

the subjects receive 35 session with sham

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 5 and 12 years.
* Meet DSM-IV criteria for autism spectrum disorder.
* Patients who have been diagnosed at least 2 years before inclusion in the study.

Exclusion Criteria

* Acute visual or hearing loss.
* Traumatic brain injury.
* Other neurological disorders: migraine, epilepsy, tuberous sclerosis ...
* Trauma at birth.
* Mental retardation.
* Pregnancy.
Minimum Eligible Age

5 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spanish Foundation for Neurometrics Development

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean Neville, MD

Role: PRINCIPAL_INVESTIGATOR

New Remedies Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New Remedies Ltd

Liverpool, Merseyside, United Kingdom

Site Status

Moises Aguilar Domingo

Liverpool, Spain, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Autism and tDCS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.